Amgen Cancer Drug Combo Cuts Death Risk by 58%
A new drug mix from Amgen gives aggressive lung cancer patients a much better shot at life.
Lung cancer moves fast. When it hits, families look for any sign of hope. Amgen may have found one.
The drugmaker tested its cancer medicine with a therapy from AstraZeneca. Together, the two drugs cut the risk of death by 58% in patients with an aggressive form of the disease. Patients lived longer with the combo than with older treatments.
Doctors call this a major win. Small-cell lung cancer is tough to beat, and standard treatments often fail after a few months. This new pairing keeps tumor cells from hiding from the immune system.
Breakthroughs like this change lives. They also show how teamwork between major drug firms creates real value for patients and everyday investors.
Source: CNBC
More from Biotech
